Author:
Min S.H.,Oh T.J.,Baek S.-I.,Lee D.-H.,Kim K.M.,Moon J.H.,Choi S.H.,Park K.S.,Jang H.C.,Lim S.
Subject
Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference19 articles.
1. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects;Ferrannini;Nat Rev Endocrinol,2012
2. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015
3. Empagliflozin and progression of kidney disease in type 2 diabetes;Wanner;N Engl J Med,2016
4. Canagliflozin and cardiovascular and renal events in type 2 Diabetes;Neal;N Engl J Med,2017
5. Drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood;Administration USFaD,2015
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献